Condition: COVID-19 · Critical Illness · Hypercytokinemia · Sponsor: University of Ulm
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
This description comes directly from the study's public registry record.
Manfred Weiss, MD · +49(0)731500 · manfred.weiss@uniklinik-ulm.de
Marion Schneider, PhD · +49(0)731500 · marion.schneider@uni-ulm.de
Always discuss trial participation with your own doctor first.
| Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine | Ulm, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05191381